Researchers have identified a potential gene therapy approach for atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G), two kidney diseases driven by overactive complement activity, according to a new mouse study. In mouse models of both diseases, delivering the gene for the complement protein factor D to liver…
Discussion
Note: This column describes the author’s own experiences with Soliris (eculizumab). Not everyone will have the same response to treatment. Consult your doctor before starting or stopping a therapy. “OK, guys, I told you Mom is cool. Your mama just got a face tat!” My youngest child furrowed his eyebrows…
Becoming educated and informed about aHUS is a good first step. Here you’ll find general information about the disease, including diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnist’s words of wisdom to help you along on your aHUS journey.
There is no cure for aHUS yet, but here you can find more information about current therapeutic approaches, as well as experimental treatments that are in the pipeline.
Get regular updates to your inbox.
